Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Sobiborowicz, Aleksandra" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
The comparison between the two most common histological subtypes of breast cancer - invasive ductal and invasive lobular breast carcinoma
Autorzy:
Fudalej, Marta
Sobiborowicz-Sadowska, Aleksandra
Mormul, Agata
Jopek, Sylwia
Borowiec, Agnieszka
Sikorski, Piotr
Patera, Janusz
Deptała, Andrzej
Badowska-Kozakiewicz, Anna M.
Powiązania:
https://bibliotekanauki.pl/articles/44426576.pdf
Data publikacji:
2024-04-07
Wydawca:
Medical Education
Tematy:
immunohistochemistry
invasive lobular carcinoma
invasive ductal carcinoma
Opis:
Introduction: Invasive lobular carcinoma (ILC) occurs in 5–15% of all cases of breast cancer. In most studies, it is found to be more common among older patients, form larger tumours and present with ill-defined margins, in comparison to invasive ductal carcinoma (IDC). Material and methods: Histological preparations were obtained from 651 patients suffering from breast cancer. Preparations stained with hematoxylin and eosin were used to identify tumour type and grading. Samples underwent a basic molecular profile evaluation encompassing ER (oestrogen receptor), PR (progesterone receptor) and human epidermal growth factor receptor 2 (HER2) expression. Results: 592 cases of IDC and 59 cases of ILC were detected. The median age was 60 in both groups. While there were no statistically significant differences between IDC and ILC in nodal status and tumour size for all age groups, IDC was more frequently diagnosed at higher grading (G3). G3 accounted for 32% of all IDC specimens compared to only 13% of ILC specimens. In both groups, the most prevalent combination of hormone receptors was ER+/PR+/HER2-. The differences in ER and PR expression were statistically significant; both were assessed as positive in most ILC cases and just over half of IDC. No HER2 amplification was noted in most cases in both cancer subtypes. Conclusions: In our study, IDC and ILC showed no difference with respect to patients’ median age at the diagnosis and local disease advancement defined by TNM. ILC cases were hormone-dependent and HER2-negative more frequently than IDC. Grade 3 tumours accounted for a higher proportion of IDC cases. This was in line with several other clinicopathological analyses of breast cancer. However, there are also several papers indicating ILC’s association with favourable prognostic features, not only in terms of hormone receptors and HER2 expression but also tumour size and nodal involvement. This underlines the fact that clear differences between IDC and ILC prognosis still cannot be established.
Źródło:
OncoReview; 2024, 14, 1; 9-15
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
ELF3 as an important factor in carcinogenesis – a brief review of the recent studies
Autorzy:
Domańska, Julia
Poboży, Kamil
Kuryłek, Michał
Fudalej, Marta M.
Sobiborowicz, Aleksandra
Deptała, Andrzej
Badowska-Kozakiewicz, Anna M.
Powiązania:
https://bibliotekanauki.pl/articles/1035652.pdf
Data publikacji:
2020
Wydawca:
Medical Education
Tematy:
ELF3
carcinogenesis
molecular biology
Opis:
Introduction and objective: E74-like transcription factor 3 (ELF3) is mainly expressed in epithelial tissue, being responsible for differentiation and regeneration. Furthermore, it plays a role in inflammation, remodeling, allergy regulation and apoptosis. Various studies on ELF3 conducted since 1997 have also proved its connection with carcinogenesis and metastasis. This review summarizes recent advances in understanding the role of ELF3 in the following cancers: ampullary, bladder, breast, gastric, hepatocellular, nasopharyngeal, thyroid, lung and ovarian ones. State of knowledge: There are still many unresolved and undiscovered issues regarding ELF3 mutations, however, based on research since 2016, a link to many signaling pathways important for carcinogenesis has been shown. There is no simple correlation between a specific ELF3 mutation and effect on cancer cells. In various types of cancers, ELF3 is associated with other pathways, and modifications exerted by silencing or amplifying its or associated genes, cause different effects in patient prediction. An example of the effect of ELF3 on tumor progression is achieved by negatively regulating the ZEB1 transcription factor responsible for metastasis. WNT, RAS, Akt, mTOR, HER2, Cyclin D, IRF6 are other ELF3-related factors that affects pathways crucial for tumorigenesis. Conclusions: Further research and attempts to use ELF3 in the treatment and prognosis of cancer appear to be beneficial.
Źródło:
OncoReview; 2020, 10, 2; 77-81
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies